Etablissement Français du Sang   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Saint-Denis France (2000)

Organization Overview

First Clinical Trial
2003
NCT00225875
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Etablissement francais du sang | Etablissement Français du Sang | ETABLISSEMENT FRANCAIS DU SANG (EFS)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Graft vs Host Disease (Phase 2)

Ischemia (Phase 2)

Melanoma (Phase 1)

Neoplasms (Phase 2)

Osteoarthritis (Phase 2)

Peripheral Arterial Disease (Phase 2)

Purpura (Phase 2)

Purpura, Thrombocytopenic (Phase 2)

Purpura, Thrombocytopenic, Idiopathic (Phase 2)

Stroke (Phase 1)

Thrombocytopenia (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 14
  • # of Trial APIs: 13